Navigation Links
U-M Medical School and MedImmune join forces to accelerate search for new therapies
Date:11/21/2011

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects.

The three-year strategic collaboration will bring scientists from one of the nation's top medical research institutions together with scientists from one of the world's leading developers of biologic therapies.

UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

This type of translational and pre-clinical research is designed to identify and confirm the specific molecules and genes involved in causing disease, and potential molecules and cell-based therapies to treat or prevent them.

"We are thrilled to partner with MedImmune in a collaborative and creative way to bring new innovations to market," says Steven Kunkel, Ph.D., senior associate dean for research at the U-M Medical School and Endowed Professor of Pathology Research. "This strategic partnership, one of the first of its kind for our institution, speaks to our desire to collaborate with industry to accelerate translation of U-M's cutting-edge research to impact patients."

The new agreement goes beyond the traditional type of academic-industry research relationship, in which companies fund projects such as clinical trials, or license patents on discoveries made by university scientists and develop them on their own. In this new type of agreement, scientists from medical schools and industry collaborate closely on projects while also preserving academic freedom, research integrity and both sides' rights to intellectual property for discoveries.

"This new horizon in industry-academic partnership ultimately benefits patients, who demand new and better options for treating diseases," says Norman Greenberg, Ph.D., MedImmune's Vice President for Oncology Research and Development. "New types of partnerships between academic biomedical powerhouses such as Michigan, and industry leaders such as MedImmune, are needed to accelerate the search for those options."

The initial focus on oncology leverages the strength of the U-M Comprehensive Cancer Center.

U-M cancer scientists, led by center director Max Wicha, M.D., have won more research grant dollars from the National Cancer Institute than researchers at any other academic medical center.

"Working with MedImmune to explore new ways to target treatments is a natural progression of the basic scientific discoveries that our teams have made in the last decade," says Wicha, who is also the Distinguished Professor of Oncology in the Department of Internal Medicine at the U-M Medical School.


'/>"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. New smart material could help tap medical potential of tissue-penetrating light
2. CDC and Prevention awards Mayo Clinic an international medical education grant
3. New international health survey of sicker adults: Those with a medical home fare better
4. Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients
5. University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients
6. Teen Pot Use Unaffected by Medical Marijuana Law: Study
7. Report calls for creation of a biomedical research and patient data network for more accurate classification of diseases, move toward precision medicine
8. Diagnostic physicians at increased risk for medical malpractice claims due to communication failures
9. Medical researchers ID potential new drug target that could stop debilitating effects of MS
10. Ghost Writing Persists in Major Medical Journals
11. Harvard Medical School and EPFL launch program targeting neurological disabilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: